Pfizer Inc.'s new experimental heart drug is dead, but the dual approach the company was testing - boosting good cholesterol while lowering the bad - is very much alive, specialists said earlier this month.
People with low levels of LDL cholesterol are more likely to have Parkinson's disease than people with high LDL levels, according to University of North Carolina at Chapel Hill researchers.
